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e446antiarrhythmic drugs averaged 3.6 (range 2 to 5) in control patients
and 3.8 (range 2 to 5) in the intervention group. The number of
antihypertensive drugs was the same, albeit with different ranges as
reported in the Results: 3.6 (range 3 to 5) and 3.8 (range 3 to 5),
respectively. The use of 5 antiarrhythmic drugs in a single patient
is incompatible with current guidelines (7).
According to Ioannidis’ seminal essay (8), several corollaries
for a possible false result might apply to the Pokushalov et al.
study (1). The likelihood that research ﬁndings are true decreases
with a smaller sample size (corollary 1); greater ﬂexibility in
designs, deﬁnitions, outcomes, and analytical methods (corollary
4); greater ﬁnancial or other interests and preconceived ideas in
a scientiﬁc ﬁeld (corollary 5); and hotter research topics (corol-
lary 6). In conclusion, the methodological drawbacks in the
report of Pokushalov et al. (1) cast doubt on its validity, which
clearly does not comply with CONSORT standards (3). Our
observations highlight the necessity to have the design, methods,
statistics, and conclusions of the Pokushalov et al. report revised
(1) and to continue remaining vigilant about the peer-review
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APPENDIX
For supplemental material, please see the online version of this letter.ReplyFirst-in-Humans Randomized Clinical
Trial of Renal Denervation for Atrial
Arrhythmia Raises ConcernWe appreciate the interest that Dr. Staessen and colleagues have
expressed regarding our recently published study (1). We have
addressed each of the issues.
1. The original protocol identiﬁed ofﬁce systolic blood pressure
(BP) at 2 years, not recurrence of atrial ﬁbrillation (AF) at
1 year, as the primary endpoint that should have informed the
sample size calculations. The number of patients actually
randomized was 27, 1 more than required according to
last version of the protocol at the registry Website, and
82% less than ﬁrst planned for (N ¼ 150).
The study was initially registered with a larger estimated sample
size, formally anticipating correction or revision as the study pro-
gressed based on the results of a planned interim analysis and the
pilot study. The hypothesis of the study formally stated was renal
ablation combined with pulmonary vein isolation (PVI) in patients
with resistant hypertension and AF may reduce blood pressure and
reduce the burden of AF. The initial sample size took into account
anticipated BP control with the planned update to address the AF
rates. Because there was absolutely no data to allow a formal sample
size based on AF control, it was impossible to do so initially. Data
analysis of the initial 27 patients with at least 1 year of follow-up
yielded very positive results, and, as a result, the pilot phase of
the study was deemed closed.
2. The discrepancy is especially worrisome because the p value for
the between-group difference in the incidence of atrial
arrhythmia was only 0.033, so that adding a single control
patient (14 instead of 13) might have made the statistical
signiﬁcance.
Including an additional patient in the control group does not have
any signiﬁcant effect on the main conclusions. We conducted
a sensitivity analysis, and it showed that when we exclude the patient
with the recurrence in the control group, the worst case scenario, the
p value changed to 0.043 and remained statistically signiﬁcant.
3. The results of atrial ablation in the control group were dismal.
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PVI were suboptimal, but not surprisingly, given that two thirds
had persistent AF, a group in whom extra efforts beyond PVI
alone are usually required to produce a better AF outcome. In
addition, there are no data on the effectiveness of catheter ablation
in patients with resistant hypertension; however, hypertension is
a well-established predictor of recurrence of AF after PVI. Given
the presence of persistent AF and resistant hypertension, the efﬁ-
cacy results obtained in the control group are very much in keeping
with published data and clinical experience.
4. Previous use of amiodarone was an exclusion criterion in the
published paper, but not in any version of the design in the trial
registry.
Amiodarone use was an exclusion criterion, as clearly noted in
the Methods section of the paper. Also, this information was
available in the full version of the protocol.
5. The original exclusion criterion of secondary atrial hypertension
was changed to secondary hypertension without mention of the
diagnostic procedures.
All patients underwent a standard full range of diagnostic
procedures to evaluate inclusion and exclusion criteria, including
the presence of secondary hypertension.
6. At variance with the CONSORT statement, the number of
patients screened and invited remains unreported.
The published version of the study had been shortened to
comply with an editorial request. We screened 42 patients to
generate a 27-patient cohort.
7. The Pokushalov et al. (1) trial was registered as investigator
driven without industry sponsor.
There was no ﬁnancial or other support from industry.
8. Researchers were originally located in Novosibirsk and Athens.
Patient enrollment was originally planned from Russian and
Greek sites, but due to unanticipated and unrelated local issues,
the Greek institution did not participate.
9. An employee from industry coauthored the published report. The
group, who ﬁrst reported on the blanking period and also received
industry support, was also added at the publication stage.
One of the coauthors was employed by industry, but at the time
of the study had no involvement in renal artery denervation, nor did
his employer. He served as an advisor, and his employer’s products
were not used in this study. No other member of the authorship
team received ﬁnancial support from industry for this study.
10. Pokushalov et al. (1) excluded the ﬁrst 3 months after
pulmonary vein isolation from the analysis of recurrent AF.
This so-called blanking period should not have been longer
than 2 to 4 weeks because recurrence of AF signiﬁcantly
decreases after 1 month and thereafter remains stable.
We have scrupulously adhered to the Heart Rhythm Society
(HRS), European Heart Rhythm Association (EHRA), European
Cardiac Arrhythmia Society (ECAS) guidelines for the manage-
ment of AF, which stipulate a blanking period of 3 months. The
paper referenced, of which Dr. Steinberg was a senior author, also
concluded that 3 months is a reasonable blanking period.11. Moreover, all of the patients of Pokushalov et al. (1) were
treated with propafenone or ﬂecainide for 6 weeks after the
procedure.
The HRS/EHRA/ECAS guidelines for the management of AF
indicate the common practice of early post-procedure antiar-
rhythmic drug therapy, which was discontinued before the
completion of the blanking period.
12. The published methods are not detailed enough to allow an
independent replication of the study.
We used a technique of renal denervation recently described by
Krum et al. (see reference 14 in our paper) for which there is ample
description to replicate the results.
13. The catheter used to stimulate the renal nerves is not
mentioned.
High-frequency stimulation was performed via the ablation
catheter, as is clearly noted in the Methods section.
14. An exhaustive Internet search for the Stimulator B-53 led us to
http://www.biotok.ru. This company is currently located in
Tomsk, not in St. Petersburg.
The stimulator was manufactured by a Russian concern and has
been used in many of our previously published studies of ablation
of ganglionated plexi. It is correct that this company is located
in Tomsk. The editorial staff inadvertently inserted the city
St. Petersburg, which should have been corrected on the proofs.
15. We could not access their Website because of an HTTP 500
Internal Server Error.
If the authors had difﬁculty accessing their Website, we
suggest that they try again or consider calling them by phone (the
director of company is Aleksandr Oferkin, telephone number
þ79059918134).
16. Furthermore, the Pokushalov et al. (1) paper does not provide
any information on the technique or reproducibility of the
echocardiographic measurements.
Echocardiographic measurements were a secondary endpoint;
only standard measurement techniques were used, and results were
reported and presented in a conventional manner.
17. There are possible differences between described and applied
statistical methods. The authors stated that continuous vari-
ables were presented as mean  SD and analyzed by a Student
t test. Systolic/diastolic blood pressure averaged 178 
8 mm Hg/96  4 mm Hg in 14 control patients and 181 
7 mm Hg/97  6 mm Hg in 13 patients of the intervention
group. For the blood pressure level, SDs around 8 mm Hg
systolic and 5 mm Hg diastolic seem unrealistic unless patients
were selected within narrow BP limits.
The patients indeed had narrow BP limits, and the statistical
analysis is straightforward (Fig. 1A).
18. Reportedly, in the intervention group, the decrease in blood
pressure at 12 months averaged 25  5 mm Hg systolic
and 10  2 mm Hg diastolic, whereas the change read from
Figure 5 was 25  3 mm Hg systolic.
In this ﬁgure, 95% conﬁdence intervals were used (Fig. 1B).
Figure 1 Systolic/Diastolic Blood Pressure
(A) Systolic/diastolic blood pressure at baseline is presented as mean  SD. (B) Systolic/diastolic blood pressure relative to baseline at 12 months is presented
as mean  SD and analyzed by Student t test.
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and the BP changes digitized from Figure 5, showed that the
measure of spread for both BP and BP decrease was probably
not SD, but more likely SE.
The statistical analysis and data as published are correct
(Fig. 1B).
20. Pokushalov et al. (1) did not report key test statistics and
rounded measures of central tendency and spread to a single
meaningful digit. In a parallel-group trial, p values for the
within-group changes in an outcome variable provide some
information, but the main test statistics should rest on
baseline-adjusted between-group differences in the endpoint.
Pokushalov et al. (1) did not show these key statistical
parameters.This paper uses the traditional form of statistical analysis. The
limited sample size did not allow a stratiﬁed log-rank test or
another multivariate survival analysis to be conducted, nor did we
plan to do so. By design, the analyses were exploratory in nature,
and the study was considered a pilot investigation.
21. Furthermore, the echocardiographic results were not consis-
tently reported throughout paper. Table 1 shows baseline values
only for left atrial diameter and left ventricular ejection fraction.
Next, Table 2 gives changes from baseline in thickness of the
interventricular septum, posterior wall, left ventricular internal
diameter, and left ventricular mass index, for which baseline
values were not given.
Echocardiographic measurements were a secondary endpoint;
therefore, they were not presented in the paper’s Table 1.
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unusual units: centimeters instead of millimeters for the inter-
ventricular septum, the posterior wall, and the left ventricular
internal diameter, and g/m, not g/m2, for left ventricular mass
index. This issue is not trivial, as the changes in left ventricular
walls and internal diameter were small with average within-
group changes ranging from 0.1 mm to 1 mm. Rounding
measures of central tendency and spread to a single meaningful
decimal and reporting left ventricular echocardiographic
measurements in centimeters rather than millimeters makes it
difﬁcult to reproduce p values from the published data.
Echocardiographic measurements were a secondary endpoint,
and the presentation and analyses are similar to those of many
published studies.
23. One other potential inaccuracy pertains to the number of drugs
taken. According to Table 1 (1), the number of antiarrhythmic
drugs averaged 3.6 (range 2 to 5) in control patients and 3.8
(range 2 to 5) in the intervention group. The number of
antihypertensive drugs was the same, albeit with different
ranges as reported in the Results: 3.6 (range 3 to 5) and 3.8
(range 3 to 5), respectively. The use of 5 antiarrhythmic drugs
in a single patient is incompatible with current guidelines.
The number of antiarrhythmic drugs represents the number of
previous failed treatments, not active treatment, as has been
incorrectly assumed. This count was accurate as was the count for
the number of antihypertensive drugs, coincidentally similar to the
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